Supercharged immune cells take on advanced cancers
NCT ID NCT07106814
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then given back as an infusion. The main goal is to check safety, but researchers will also look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metabolically armed tumor-infiltrating lymphocytes (Meta10-TIL)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapy.
- What could go wrong
- This is a very early, small trial (36 people) focused on safety, so it is unknown if the treatment will be effective. There may be side effects from the cell infusion or from the conditioning regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?